uniQure NV (QURE)

26.58
0.22 0.83
NASDAQ : Health Technology
Prev Close 26.36
Open 25.67
Day Low/High 25.10 / 27.32
52 Wk Low/High 13.71 / 43.23
Volume 199.54K
Avg Volume 280.60K
Exchange NASDAQ
Shares Outstanding 30.80M
Market Cap 821.74M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

QURE Crosses Above Average Analyst Target

QURE Crosses Above Average Analyst Target

In recent trading, shares of uniQure N. .

UniQure Announces Publication In The Journal Blood Of Clinical Data From Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B

UniQure Announces Publication In The Journal Blood Of Clinical Data From Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B

Data Demonstrate Clinical Effectiveness and Superior Immunogenicity Profile of AAV5 Gene Therapy in Severe and Moderate-Severe Hemophilia B Patients

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

UniQure Announces Presentations At The 59th American Society Of Hematology (ASH) Annual Meeting

UniQure Announces Presentations At The 59th American Society Of Hematology (ASH) Annual Meeting

~ New Nonclinical Data on AMT-061 to be Presented Saturday, December 9, 2017 ~

First Week of December 15th Options Trading For uniQure (QURE)

First Week of December 15th Options Trading For uniQure (QURE)

Investors in uniQure N. .

uniQure Reaches Analyst Target Price

uniQure Reaches Analyst Target Price

In recent trading, shares of uniQure N. .

UniQure Announces FDA Orphan Drug Designation For AMT-130 In Huntington's Disease

UniQure Announces FDA Orphan Drug Designation For AMT-130 In Huntington's Disease

~ First Investigational Gene Therapy in Huntington's Disease to Receive Designation ~

UniQure Announces Company Participation At Citi Healthcare Conference

UniQure Announces Company Participation At Citi Healthcare Conference

Live webcast of gene therapy panel discussion on Thursday, September 7 at 11:00 am EDT

UniQure Reacquires Development And Commercialization Rights For Its Gene Therapy Candidate In Hemophilia B

UniQure Reacquires Development And Commercialization Rights For Its Gene Therapy Candidate In Hemophilia B

~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~

TheStreet Quant Rating: D- (Sell)